Showing results (111-120 of 4,543) with videos related to

Sort By:
Pageof 455
Hepatology (Baltimore, Md.)|September 9, 2024
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosisZobair M Younossi, Maria Stepanova, Andrei Racila, et al.
Cyberpsychology & Behavior : the Impact of the Internet, Multimedia and Virtual Reality on Behavior and Society|February 16, 2008
The cyber-aspects of virtual communities: free downloader ethics, cognition, and perceived service qualityChin-Feng Lin
Behavior Research Methods|April 14, 2009
Systematic behavior research for understanding consumer decision makingChin-Feng Lin
Journal of Medical Systems|August 13, 2010
Mobile telemedicine: a survey studyChin-Feng Lin
Hepatology (Baltimore, Md.)|July 18, 2018
Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource UseMehmet Sayiner, Pegah Golabi, Maria Stepanova, et al.
Alimentary Pharmacology & Therapeutics|November 12, 2022
Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based studyYusuf Yilmaz, Ahmet Eren Toraman, Ceyda Alp, et al.
Annals of Hepatology|February 10, 2025
Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK)Zobair M Younossi, James M Paik, Linda Henry, et al.
Obesity Surgery|February 2, 2010
Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver diseaseMaria Stepanova, Noreen Hossain, Arian Afendy, et al.
Hepatology Communications|February 7, 2018
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver diseaseZobair M Younossi, Maria Stepanova, Nila Rafiq, et al.
Journal of Clinical and Experimental Hepatology|April 9, 2026
Self-Reported Cognitive Function in Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom TrialsZobair M Younossi, Fatema Nader, Dominic Labriola, et al.
Pageof 455